Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma

Clinical trial NCT04782609 · TERMINATED

Trial details

NCT number: NCT04782609
Sponsor: Samus Therapeutics, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Glioblastoma Multiforme (GBM)Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma Grade 3 or 4 Astrocytoma Glioblastoma Surgery

Start date: 2021-12-27
Primary completion: 2022-11-04
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.